BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...extracellular matrix components, such as fibers, which are found around tumor blood vessels. Daromun combines Darleukin...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...to mediate toxicity. Selected clinical-stage products are shown below. (A) In the Phase III study, Darleukin...
...BioCentury Online Intelligence; ClinicalTrials.gov; company web sites Company Product Description Lead indication Status Philogen S.p.A. Darleukin...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...additional models of cancer. Philogen S.p.A. has two IL-2-based fusion proteins in clinical testing: Darleukin (L19-IL2...
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

...to localize the effects of IL-2 to tumors. The most advanced are Philogen S.p.A. ’s Darleukin...
...tumor vasculature isoform of fibronectin ( FN1 ; FN), and Daromun , a combination of Darleukin...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...a mouse model of metastatic melanoma. Philogen S.p.A. has three IL-2 based products in development: darleukin...
...III for melanoma and Phase I for B cell lymphoma; daromun , a combination of darleukin...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...BCIQ: BioCentury Online Intelligence; Courier Therapeutics Inc. Company Product Description Indication(s) Status Philogen S.p.A. Darleukin (L19-IL2...
...isoform of fibronectin (FN1; FN) B cell lymphoma; melanoma Phase III Daromun (L19-IL2 + L19-TNF) Darleukin...
...said Gladstone. He said that therapies already in the clinic, such as Philogen S.p.A ’s Darleukin...
BioCentury | Feb 8, 2016
Clinical News

Fibromun: Phase III started

...an open-label, international Phase III trial to evaluate 13 million international units (MIU) of intralesional L19-IL2...
...with 400 ug intralesional L19-TNF given weekly for 4 weeks in about 214 patients. Philogen’s L19-IL2...
BioCentury | Feb 8, 2016
Clinical News

Darleukin: Phase III started

...an open-label, international Phase III trial to evaluate 13 million international units (MIU) of intralesional L19-IL2...
...to human tumor necrosis factor (TNF) . Philogen S.p.A. , Siena, Italy Product: Darleukin ( L19-IL2...
BioCentury | Jun 13, 2011
Clinical News

Darleukin: Phase II data

...A Phase II trial in 29 evaluable patients showed that IV darleukin led to 8 objective...
...Society of Clinical Oncology meeting in Chicago. Philogen S.p.A. , Siena, Italy Product: Darleukin ( L19-IL2...
BioCentury | Feb 21, 2011
Company News

Philogen, Bayer deal

...Philogen's most advanced compound, Darleukin ( L19-IL2 ), a fusion protein consisting of the human vascular...
Items per page:
1 - 10 of 15